Clinical Trials

186 enrolled

Phase 2 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03441113 2026-04-20

Extended Access of Momelotinib in Adults With Myelofibrosis

237 enrolled

Neoplasms, Primary Myelofibrosis

NCT06034002 2026-04-17

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

290 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT07441694 2026-04-15

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

218 enrolled

Phase 1 Not yet recruiting

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT07527221 2026-04-14

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

40 enrolled

Phase 1 Not yet recruiting

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT07529951 2026-04-14

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

60 enrolled

Polycythemia Vera, Primary Myelofibrosis

NCT04562389 2026-04-09

SENTRY

353 enrolled

Myeloproliferative Disorders, Primary Myelofibrosis

NCT07008118 2026-04-06

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

120 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06351631 2026-04-02

MK-3543-017

Phase 3 Recruiting

400 enrolled

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

210 enrolled

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT05936359 2026-03-24

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

225 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

330 enrolled

Neoplasms, Primary Myelofibrosis

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

327 enrolled

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

MyeloidOther hematologic neoplasmThoracic

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

MyeloidOther hematologic neoplasmOther neoplasm

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06397313 2025-09-23

POTAMI-61

Phase 2 Recruiting

230 enrolled

Neoplasm Metastasis, Primary Myelofibrosis

NCT05223920 2025-09-22

MK-3543-005

81 enrolled 13 charts

Thrombocythemia, Essential, Primary Myelofibrosis

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06378437 2025-08-19

A Study of GLB-001 in Patients With Myeloid Malignancies

108 enrolled

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

21 enrolled

Neoplasms, Primary Myelofibrosis

NCT04717414 2025-07-10

INDEPENDENCE

Classical hematologyMyeloid

313 enrolled

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Phase 2 Active not recruiting

90 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05423691 2025-04-13

TREG108

24 enrolled

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Thrombocytosis, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT05488548 2025-01-14

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

75 enrolled

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02268253 2025-01-06

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Phase 1/2 Completed

82 enrolled 15 charts

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03755518 2024-12-12

FREEDOM

Phase 3 Terminated

38 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT00522990 2024-08-02

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

LymphoidMyeloidOther hematologic neoplasm

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04637009 2024-08-02

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Phase 1 Terminated

20 enrolled

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Pyloric Stenosis, Hypertrophic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04655118 2024-05-10

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Phase 2 Recruiting

121 enrolled

Mastocytosis, Systemic, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Classical hematologyMyeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT05927012 2023-11-24

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Phase 2 Withdrawn

Myelodysplastic Syndromes, Anemia, Iron-Deficiency, Primary Myelofibrosis

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Terminated

1 enrolled

Neoplasms, Primary Myelofibrosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Classical hematologyMyeloid

95 enrolled 32 charts

Anemia, Primary Myelofibrosis

NCT02124746 2023-06-18

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

87 enrolled 17 charts

Hematologic Diseases, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04896112 2023-06-18

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Phase 1 Withdrawn

Polycythemia Vera, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT02440685 2023-06-07

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors